|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Optimal Imaging Standards for Metastatic Castration-Sensitive Prostate Cancer
|
|
Michael Morris, MD
|
| Michael Morris discusses optimal imaging standards for metastatic hormone-sensitive prostate cancer. He explains that conventional imaging methods like PSA tracking are insufficient for monitoring disease progression in the era of advanced androgen receptor signaling inhibitors.
|
|
|
|
|
|
|
|
|
|
|
|
|
Redefining Low-Volume Metastatic Prostate Cancer in the Era of PSMA PET Imaging
|
|
Oliver Sartor, MD
|
| Oliver Sartor discusses his approach to treating low-volume metastatic prostate cancer. Dr. Sartor emphasizes the importance of molecular imaging, particularly PSMA PET, to define low-volume and oligometastatic disease accurately.
|
|
|
|
|
|
|
|
|
|
|
|
| CLARIFY Trial: Advancing Prostate Cancer Imaging with 64Cu-SAR-bisPSMA PET |
| Neal Shore, MD, FACS |
| Neal Shore discusses a new 64Cu-SAR-bisPSMA PET diagnostic agent for prostate cancer imaging with Phillip Koo. Dr. Shore highlights the unique features of this compound, including its bivalent structure and longer half-life compared to existing PSMA PET agents. |
|
|
|
|
|
|
|
|
|
|
|
Prostate Magnetic Resonance Imaging Utilization and Its Relationship with Advanced Prostate Cancer Detection - Beyond the Abstract
|
| Zhiyu Qian, Yu-Jen Chen, Julia Feldman et al. |
| This study analyzed the relationship between increasing prostate MRI use and advanced prostate cancer detection using SEER-Medicare data from 2004-2015. The results showed no significant association between regional MRI utilization and advanced prostate cancer rates, suggesting that the rise in advanced cases may be due to factors like the 2012 USPSTF recommendation against routine PSA screening rather than improved imaging sensitivity. |
|
|
|
|
|
| 68Ga-RM2 PET-MRI Versus MRI Alone for the Evaluation of Patients with Biochemical Recurrence of Prostate Cancer: A Single-Centre, Single-Arm, Phase 2/3 Imaging Trial - Beyond the Abstract
|
| Heying Duan, Farshad Moradi, Guido A Davidzon et al.
|
| This study assessed the diagnostic performance of 68Ga-RM2 PET/MRI compared to MRI alone in detecting prostate cancer recurrence in patients with elevated PSA levels. The findings showed that 68Ga-RM2 PET/MRI had higher detection rates and sensitivity, particularly at low PSA concentrations, while maintaining high specificity and positive predictive values similar to MRI.
|
|
|
|
|
|
|
|
|
|
|
| Comparison of 18F-Based PSMA Radiotracers with [68Ga]Ga-PSMA-11 in PET/CT Imaging of Prostate Cancer - A Systematic Review and Meta-Analysis - Beyond the Abstract
|
| Siyu Huang, MD
|
| This systematic review and meta-analysis compared 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 for prostate cancer imaging. [18F]DCFPyL showed high concordance with [68Ga]Ga-PSMA-11 in detecting metastatic lesions, making it a suitable alternative, while [18F]PSMA-1007 had higher locoregional detection but increased benign bone uptake, leading to potential false positives. More studies are needed to evaluate the clinical and logistical impacts of these radiotracers.
|
|
|
|
|
|
| Prostate-Specific Membrane Antigen Imaging Findings and Subsequent Clinical Management Among Patients with Biochemical Recurrent Prostate Cancer: A Retrospective Cohort Study
|
| Michael Leapman, MD, MHS
|
| Michael Leapman presented a retrospective cohort study on PSMA-PET imaging and subsequent clinical management in patients with biochemically recurrent prostate cancer. Among 583 patients, 76% had PSMA-positive findings, with 50% showing distant metastasis. The study showed that most patients with metastases were treated within six months, often with systemic therapy or metastasis-directed therapy, particularly in those with lower PSA levels.
|
|
|
|
|
|
| Development of a Novel Risk Stratification for Prostate Cancer Patient Candidates to Radical Prostatectomy Staged with Preoperative PSMA-PET: The Key Role of Molecular Imaging
|
| Francesco Barletta, MD
|
| Francesco Barletta introduced a novel risk stratification model for prostate cancer patients undergoing radical prostatectomy that incorporates preoperative PSMA-PET data. Analyzing data from 707 intermediate to high-risk patients, the study found that the new model significantly improved predictions of early biochemical failure (BCF) compared to existing classifications, with two-year BCF rates of 91% for intermediate, 79% for high, and 58% for very high-risk groups.
|
|
|
|
|
|
| Pre-Surgical 68Ga-PSMA-11 PET for Biochemical Recurrence Risk Assessment: A Surrogate of Pelvic Lymph Node Dissection? Follow-Up Analysis of a Multicenter Prospective Phase 3 Imaging Trial
|
| Loic Djaileb, MD, PhD
|
| Loic Djaileb presented a follow-up analysis from a multicenter prospective phase 3 imaging trial that assessed the prognostic value of pre-surgical 68Ga-PSMA-11 PET/CT in evaluating biochemical recurrence risk in prostate cancer patients. The findings indicated that the combination of local histopathology and PSMA-PET/CT performed comparably to traditional methods incorporating pelvic lymph node (pN) status for predicting biochemical recurrence-free survival, suggesting that pre-surgical PSMA-PET could serve as a surrogate for pN status in select patients.
|
|
|
|
|
|
